Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-22
2010-06-15
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S405000, C546S235000, C585S026000
Reexamination Certificate
active
07737152
ABSTRACT:
The present invention pertains to certain 6-carboaryloxy-pyrazin-2-yl-carboaryl-amines of the following formula, and pharmaceutically acceptable salts thereof, which, inter alia, inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., wherein Q is independently —N═; RP3is independently a group of the formula -J1-L1-Z; -J1L1-Z is independently —NH—Z; Z is independently C6-14carboaryl and is independently unsubstituted or substituted; RP2is independently —H; RP5is independently a group of the formula —W—Y; W is independently —O—; Y is independently C6-14carboaryl and is independently unsubstituted or substituted; and RP6is independently —H. The present invention also pertains to pharmaceutical compositions comprising such compounds.
REFERENCES:
patent: 4666828 (1987-05-01), Gusella
patent: 4683202 (1987-07-01), Mullis
patent: 4801531 (1989-01-01), Frossard
patent: 5192659 (1993-03-01), Simons
patent: 5272057 (1993-12-01), Smulson et al.
patent: 5521073 (1996-05-01), Davis et al.
patent: 5691364 (1997-11-01), Buckman et al.
patent: 5877020 (1999-03-01), Alitalo
patent: 5879672 (1999-03-01), Davis et al.
patent: 5882864 (1999-03-01), An et al.
patent: 6030831 (2000-02-01), Godowski et al.
patent: 6034103 (2000-03-01), Buckman et al.
patent: 6218529 (2001-04-01), An et al.
patent: 2003/0060629 (2003-03-01), Kuo et al.
patent: 2004/0102455 (2004-05-01), Burns et al.
patent: 2004/0235862 (2004-11-01), Burns et al.
patent: 2400101 (2004-10-01), None
patent: WO 98/52559 (1998-11-01), None
patent: WO 01/17995 (2001-03-01), None
patent: WO 02/24681 (2002-03-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 03/031406 (2003-04-01), None
patent: WO 03/037891 (2003-05-01), None
patent: WO 03/056036 (2003-07-01), None
patent: WO 2004/052868 (2004-06-01), None
patent: WO 2005/003101 (2005-01-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, p. 18.
Wolff, Manfred E., Ed. Burger's Medicinal Chemistry and Drug Discovery—Fifth Edition, New York: John Wiley & Sons, 1996, vol. 1, pp. 975-976.
Adams, R.H., et al, 1999, “Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis”,Genes Dev., vol. 13, pp. 295-306.
Angerer, L.M., et al, 1987, “Demonstration of tissue-specific gene expression by in situ hybridization”,Methods in Enzymology, vol. 152, pp. 649-661.
Bartlett, J.M.S., 2004, “Fluorescence In Situ Hybridization: Technical Overview,” in: Molecular Diagnosis of Cancer, Methods and Protocols, 2nd ed. (Series: Methods in Molecular Medicine), pp. 77-88.
Berge et al., 1977, “Pharmaceutically Acceptable Salts,”J. Pharm. Sci., vol. 66, pp. 1-19.
Brooks, P.C., et al, 1994, “Integrin ανβ3antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels”,Cell, vol. 79, pp. 1157-1164.
Brose, M.S., et al, 2002, “BRAFandRASmutations in human lung cancer and melanoma”,Cancer Research, vol. 62, pp. 6997-7000.
Brückner, K., et al, 1997, “Tyrosine phosphorylation of transmembrane ligands for Eph receptors”,Science, vol. 275, pp. 1640-1643.
Bruder, J.T., et al, 1992, “Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promotors requires Raf-1 kinase”,Genes&Development, vol. 6, pp. 545-556.
Calipel, A., et al., 2003, “Mutation of B-Raf in Human Choroidal Melanoma Cells Mediates Cell Proliferation and Transformation through the MEK/ERK Pathway”,J. Biol. Chem., vol. 278, pp. 42409-42418.
Cantrell, D.A., 2003, “GTPases and T cell activation”,Immunological Reviews, vol. 192, pp. 122-130.
Chan, A.C., et al, 1996, “Regulation of antigen receptor signal tgransdu8ction by protein tyrosine kinases”,Current Opin. Immunol., vol. 8, pp. 394-401.
Cohen, Y., et al, 2003, “Lack of BRAF mutation in primary uveal melanoma”,Invest. Ophthalmol. Vis. Sci., vol. 44, pp. 2876-2878.
Colville-Nash, P.R., et al, 1992, “Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications”,Annals of the Rheum. Dis., vol. 51, pp. 919-925.
Cooper, J.A., 1994, “Membrane-associated tyrosine kinases as molecular switches”,Sem. Cell Biology, vol. 5, pp. 377-387.
Courtneidge, S.A., et al, 1993, “The Src family of protein tyrosine kinases: regulation and functions”,Development 1993 Supplement, pp. 57-64.
Cowley, S., et al, 1994, “Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells”,Cell, vol. 77, pp. 841-852.
Davies, H., et al, 2002, “Mutations of theBRAFgene in human cancer”,Nature, vol. 417, pp 949-954.
Davis, S., et al, 1996, “Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning”,Cell, vol. 87, pp. 1161-1169.
Denekamp, J., 1993, “Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy”,British Journal of Radiology, vol. 66, pp. 181-196.
Dickson, B., et al, 1992, “Raf functions downstream of Ras1 in the sevenless signal transduction pathway”,Nature, vol. 360, pp. 600-603.
Dumas, J., 2001, “Protein kinase inhibitors: emerging pharmacophores 1997-2000” Expert Opinion on Therapeutic Patents, Ashley Publications, vol. 11, No. 3, pp. 405-429.
Fidler, I.J., et al, 1994, “The implications of angiogenesis for the biology and therapy of cancer metastasis”,Cell, vol. 79, pp. 185-188.
Folkman, J., 1992, “The role of angiogenesis in tumor growth”,Cancer Biology, vol. 3, pp. 65-71.
Folkman, J., 1997, “Angiogenesis and angiogenesis inhibition: an overview”,EXS, vol. 79, pp. 1-8.
Folkman, J., et al, 1992, “Angiogensis”,Journal of Biol. Chem., vol. 267, pp. 10931-10934.
Folkman, J., et al, 1995, “Angiogenesis in cancer, vascular, rheumatoid and other disease”,Nature Medicine, vol. 1, pp. 27-31.
Friedlander, et al, 1995, “Definition of two angiogenic pathways by distinct ανintegrins”,Science, vol. 270, pp. 1500-1502.
Gale, et al, 1999, “Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development”,Genes Dev., vol. 13, pp. 1055-1066.
Genot, E., et al, 2000, “Ras regulation and function in lymphocytes”,Curr. Opin. Immunol., vol. 12, pp. 289-294.
Gorden, A., et al, 2003, “Analysis ofBRAFandN-RASmutations in metastatic malanoma tissues”,Cancer Research, vol. 63, pp. 3955-3957.
Helbling, P.M., et al, 2000, “The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins inXenopus laevis”, Development, vol. 127, pp. 269-278.
Hingorani, S. R., et al., 2003, “Suppression of BRAFV599Ein Human Melanoma Abrogates Transformation”,Cancer Research, vol. 63, pp. 5198-5202.
Holland, S.J., et al, 1996, “Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands”,Nature, vol. 383, pp. 722-725. Holland, S.J., et al., 1996, Nature, vol. 383, pp. 722-725.
Ingber, et al, 1990,“Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth”,Nature, vol. 348, pp. 555-557.
Kahlon, R., et al, 1992, “Angiogenesis in atherosclerosis”,Can. J. Cardiol., vol. 8, pp. 60-64.
Karasarides, M., et al., 2004, “B-RAF is a therapeutic target in melanoma”,Oncogene, vol. 23, pp. 6292-6298.
Kolch, W., et al, 1991, &#
Gill Adrian Liam
Marais Richard Malcolm
Niculescu-Duvaz Ion
Roman Vela Esteban
Springer Caroline Joy
Michael & Best & Friedrich LLP
The Wellcome Trust Limited
Willis Douglas M
Wilson James O
LandOfFree
6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4207578